Title: | Sequential chemotherapy and myeloablative allogeneic hematopoietic stem cell transplantation for refractory acute lymphoblastic leukemia |
Authors: | Arita, Kotaro Browse this author |
Kondo, Takeshi Browse this author |
Sugita, Junichi Browse this author |
Shigematsu, Akio Browse this author |
Shiratori, Souichi Browse this author |
Wakasa, Kentaro Browse this author |
Yasumoto, Atsushi Browse this author |
Ibata, Makoto Browse this author |
Shono, Yusuke Browse this author |
Kikuchi, Misato Browse this author |
Goto, Hideki Browse this author |
Takeda, Yukari Browse this author |
Takahata, Mutsumi Browse this author |
Kato, Naoko Browse this author |
Nishio, Mitsufumi Browse this author |
Ota, Shuichi Browse this author |
Tanaka, Junji Browse this author |
Imamura, Masahiro Browse this author →KAKEN DB |
Keywords: | Acute lymphoblastic leukemia |
Allogeneic hematopoietic stem cell transplantation |
Non-CR |
Refractory leukemia |
Induction failure |
Issue Date: | Sep-2011 |
Publisher: | Springer Japan |
Journal Title: | International Journal of Hematology |
Volume: | 94 |
Issue: | 3 |
Start Page: | 291 |
End Page: | 295 |
Publisher DOI: | 10.1007/s12185-011-0919-3 |
PMID: | 21879292 |
Abstract: | The prognosis of patients receiving allogeneic hematopoietic stem cell transplantation (HSCT) for refractory acute lymphoblastic leukemia (ALL) is very poor. To improve survival rates, we attempted to intensify the conditioning regimen with daunorubicin, vincristine, prednisolone, medium-dose etoposide, cyclophosphamide, and total body irradiation (DNR/VCR/PSL plus medium-dose VP/CY/TBI). Four patients in relapse or induction failure of B-precursor ALL without other complications underwent allogeneic HSCT. Initially, chemotherapy comprising DNR 60 mg/m2 for 3 days, VCR 1.4 mg/m2 for 1 day, and PSL 60 mg/m2 for 3 days was administered, which was followed by medium-dose VP/CY/TBI; some modifications were made for individual patients. All patients achieved engraftment and complete remission after HSCT. Regimen-related toxicities were tolerable and no patient died within 100 days. Two patients were alive without disease on days 563 and 1055. The third patient relapsed on day 951, while the fourth died on day 179 without disease. Our results indicate that intensified myeloablative HSCT should be considered for patients with refractory ALL. |
Rights: | The final publication is available at www.springerlink.com |
Type: | article (author version) |
URI: | http://hdl.handle.net/2115/47958 |
Appears in Collections: | 医学院・医学研究院 (Graduate School of Medicine / Faculty of Medicine) > 雑誌発表論文等 (Peer-reviewed Journal Articles, etc)
|